Jeffrey Vietri1, Stuart J Turner2, Haijun Tian3, Gina Isherwood4, Maria-Magdalena Balp5, Susan Gabriel2. 1. Kantar Health, Health Outcomes Practice, Horsham, Pennsylvania. Electronic address: Jeffrey.vietri@kantarhealth.com. 2. Novartis Pharmaceutical Corporation, US Health Economics and Outcomes Research, East Hanover, New Jersey. 3. Novartis Pharmaceutical Corporation, Global Medical Affairs, East Hanover, New Jersey. 4. Kantar Health, Health Outcomes Practice, Epsom, Surrey, United Kingdom. 5. Novartis Pharma AG, IHC, Basel, Switzerland.
Abstract
BACKGROUND: Chronic idiopathic (also called spontaneous) urticaria (CIU/CSU) is the most common form of chronic urticaria and has been associated with impairment to health outcomes, although the effect has never been assessed using a nationally representative sample in the United States. OBJECTIVES: To assess the burden of CIU/CSU from the patients' perspective in terms of health related quality of life, impairment to work and nonwork activities, and health care resource use. METHODS: Data were obtained from the US National Health and Wellness Survey. Current use of a prescription for the treatment of chronic hives was used as a proxy for CIU/CSU. Patients with CIU/CSU in the proxy group were matched 1:4 to respondents without chronic hives using survey year, sex, age, and race. Generalized linear models were adjusted for comorbidities, smoking, body mass index, and health insurance status. Outcome measures included the Medical Outcomes Study 12-Item and 36-Item Short Form Health Surveys; self-reported depression, anxiety, and sleep difficulties; the Work Productivity and Activity Impairment questionnaire, and health care resource use. RESULTS: After matching and adjustment for covariates, those currently using a prescription for chronic hives had mental component summary scores 5.7 points lower, physical component summary scores 6.5 points lower, and health utility scores 0.11 points lower than controls, as well as higher adjusted odds of reporting depression, anxiety, and sleep difficulties. Mean adjusted work impairment was approximately double in prescription-treated chronic hives relative to controls, as was frequency of health care visits. CONCLUSION: Chronic hives substantially affects quality of life, nonwork activities, capacity to work, and health care use, providing further evidence of a high burden of CIU/CSU across multiple health outcomes and unmet need for effective treatment.
BACKGROUND: Chronic idiopathic (also called spontaneous) urticaria (CIU/CSU) is the most common form of chronic urticaria and has been associated with impairment to health outcomes, although the effect has never been assessed using a nationally representative sample in the United States. OBJECTIVES: To assess the burden of CIU/CSU from the patients' perspective in terms of health related quality of life, impairment to work and nonwork activities, and health care resource use. METHODS: Data were obtained from the US National Health and Wellness Survey. Current use of a prescription for the treatment of chronic hives was used as a proxy for CIU/CSU. Patients with CIU/CSU in the proxy group were matched 1:4 to respondents without chronic hives using survey year, sex, age, and race. Generalized linear models were adjusted for comorbidities, smoking, body mass index, and health insurance status. Outcome measures included the Medical Outcomes Study 12-Item and 36-Item Short Form Health Surveys; self-reported depression, anxiety, and sleep difficulties; the Work Productivity and Activity Impairment questionnaire, and health care resource use. RESULTS: After matching and adjustment for covariates, those currently using a prescription for chronic hives had mental component summary scores 5.7 points lower, physical component summary scores 6.5 points lower, and health utility scores 0.11 points lower than controls, as well as higher adjusted odds of reporting depression, anxiety, and sleep difficulties. Mean adjusted work impairment was approximately double in prescription-treated chronic hives relative to controls, as was frequency of health care visits. CONCLUSION: Chronic hives substantially affects quality of life, nonwork activities, capacity to work, and health care use, providing further evidence of a high burden of CIU/CSU across multiple health outcomes and unmet need for effective treatment.
Authors: Pavel Kolkhir; Ana M Giménez-Arnau; Kanokvalai Kulthanan; Jonny Peter; Martin Metz; Marcus Maurer Journal: Nat Rev Dis Primers Date: 2022-09-15 Impact factor: 65.038
Authors: M Maurer; M Abuzakouk; F Bérard; W Canonica; H Oude Elberink; A Giménez-Arnau; C Grattan; K Hollis; A Knulst; J-P Lacour; C Lynde; A Marsland; D McBride; A Nakonechna; J Ortiz de Frutos; C Proctor; G Sussman; C Sweeney; H Tian; K Weller; D Wolin; M-M Balp Journal: Allergy Date: 2017-07-10 Impact factor: 13.146
Authors: Woo Jung Song; Mira Choi; Dong Hun Lee; Jae Woo Kwon; Gun Woo Kim; Myung Hwa Kim; Mi Ae Kim; Min Hye Kim; Byung Keun Kim; Sujeong Kim; Joung Soo Kim; Jung Eun Kim; Ju Young Kim; Joo Hee Kim; Hyun Jung Kim; Hye One Kim; Hyo Bin Kim; Joo Young Roh; Kyung Hee Park; Kui Young Park; Han Ki Park; Hyunsun Park; Jung Min Bae; Ji Yeon Byun; Dae Jin Song; Young Min Ahn; Seung Eun Lee; Young Bok Lee; Joong Sun Lee; Ji Hyun Lee; Kyung Hwan Lim; Young Min Ye; Yoon Seok Chang; You Hoon Jeon; Jiehyun Jeon; Mihn Sook Jue; Sun Hee Choi; Jeong Hee Choi; Gyu Young Hur; Young Min Park; Dae Hyun Lim; Sang Woong Youn Journal: Allergy Asthma Immunol Res Date: 2020-07 Impact factor: 5.764
Authors: M Maurer; K Houghton; C Costa; F Dabove; L F Ensina; A Giménez-Arnau; G Guillet; G N Konstantinou; M Labrador-Horrillo; H Lapeere; R Meshkova; E A Pastorello; M Velásquez-Lopera; L M Tamayo Quijano; C Vestergaard; N Chapman-Rothe Journal: World Allergy Organ J Date: 2018-11-16 Impact factor: 4.084
Authors: Ana M Gimenéz-Arnau; Sheldon Spector; Evgeniya Antonova; Benjamin Trzaskoma; Karin Rosén; Theodore A Omachi; Donald Stull; Maria-Magdalena Balp; Thomas Murphy Journal: Clin Transl Allergy Date: 2016-08-18 Impact factor: 5.871